Treating Residual Disease in Upper GI Cancers Following FLOT Treatment

James Zoeller discussed various aspects of his cancer care after a RCC diagnosis with Hannah D. McManus, MD, and Allison Brown, BSN, RN, RN-BC.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

The CheckMate 9DW trial found that nivolumab and ipilimumab elicited a median OS of 23.7 months compared with 20.6 months from lenvatinib or sorafenib.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

In the phase 3 COMPETE trial, ITM-11 met its primary end point of PFS and showed a favorable trend with respect to OS in GEP-NETs.

The safety profile of trastuzumab deruxtecan in the phase 3 DESTINY-Gastric04 trial was consistent with the established safety profile of the agent.